These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 18776709)

  • 21. Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats.
    Laurent D; Gounarides JS; Gao J; Boettcher BR
    Diabetes Obes Metab; 2009 Jun; 11(6):632-6. PubMed ID: 19175377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
    Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
    Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of peroxisome proliferator activated receptors (PPAR)-γ and -α agonists on cochlear protection from oxidative stress.
    Sekulic-Jablanovic M; Petkovic V; Wright MB; Kucharava K; Huerzeler N; Levano S; Brand Y; Leitmeyer K; Glutz A; Bausch A; Bodmer D
    PLoS One; 2017; 12(11):e0188596. PubMed ID: 29182629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates.
    Lefebvre AM; Peinado-Onsurbe J; Leitersdorf I; Briggs MR; Paterniti JR; Fruchart JC; Fievet C; Auwerx J; Staels B
    Arterioscler Thromb Vasc Biol; 1997 Sep; 17(9):1756-64. PubMed ID: 9327774
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MK-0767, a novel dual PPARalpha/gamma agonist, displays robust antihyperglycemic and hypolipidemic activities.
    Doebber TW; Kelly LJ; Zhou G; Meurer R; Biswas C; Li Y; Wu MS; Ippolito MC; Chao YS; Wang PR; Wright SD; Moller DE; Berger JP
    Biochem Biophys Res Commun; 2004 May; 318(2):323-8. PubMed ID: 15120604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.
    Balasubramanian R; Gerrard J; Dalla Man C; Firbank MJ; Lane A; English PT; Cobelli C; Taylor R
    Diabet Med; 2010 Feb; 27(2):150-6. PubMed ID: 20546257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combining beta-adrenergic and peroxisome proliferator-activated receptor gamma stimulation improves lipoprotein composition in healthy moderately obese subjects.
    Hughes TA; Stentz F; Gettys T; Smith SR
    Metabolism; 2006 Jan; 55(1):26-34. PubMed ID: 16324916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Wogonin ameliorates hyperglycemia and dyslipidemia via PPARα activation in db/db mice.
    Bak EJ; Kim J; Choi YH; Kim JH; Lee DE; Woo GH; Cha JH; Yoo YJ
    Clin Nutr; 2014 Feb; 33(1):156-63. PubMed ID: 23623334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination.
    Tsuchida A; Yamauchi T; Takekawa S; Hada Y; Ito Y; Maki T; Kadowaki T
    Diabetes; 2005 Dec; 54(12):3358-70. PubMed ID: 16306350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.
    Harrity T; Farrelly D; Tieman A; Chu C; Kunselman L; Gu L; Ponticiello R; Cap M; Qu F; Shao C; Wang W; Zhang H; Fenderson W; Chen S; Devasthale P; Jeon Y; Seethala R; Yang WP; Ren J; Zhou M; Ryono D; Biller S; Mookhtiar KA; Wetterau J; Gregg R; Cheng PT; Hariharan N
    Diabetes; 2006 Jan; 55(1):240-8. PubMed ID: 16380499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs).
    Staels B; Schoonjans K; Fruchart JC; Auwerx J
    Biochimie; 1997; 79(2-3):95-9. PubMed ID: 9209702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.
    Kim MK; Chae YN; Choi SH; Moon HS; Son MH; Bae MH; Choi HH; Hur Y; Kim E; Park YH; Park CS; Kim JG; Lim JI; Shin CY
    Eur J Pharmacol; 2011 Jan; 650(2-3):673-81. PubMed ID: 20974124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus.
    Nagashima K; Lopez C; Donovan D; Ngai C; Fontanez N; Bensadoun A; Fruchart-Najib J; Holleran S; Cohn JS; Ramakrishnan R; Ginsberg HN
    J Clin Invest; 2005 May; 115(5):1323-32. PubMed ID: 15841215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes.
    Massaro M; Scoditti E; Pellegrino M; Carluccio MA; Calabriso N; Wabitsch M; Storelli C; Wright M; De Caterina R
    Pharmacol Res; 2016 May; 107():125-136. PubMed ID: 26976796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice.
    Choi WS; Lee JJ; Kim Y; Kim IS; Zhang WY; Myung CS
    Arch Pharm Res; 2011 Apr; 34(4):615-24. PubMed ID: 21544727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
    Hennuyer N; Tailleux A; Torpier G; Mezdour H; Fruchart JC; Staels B; Fiévet C
    Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1897-902. PubMed ID: 15994444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients.
    Brisson D; Ledoux K; Bossé Y; St-Pierre J; Julien P; Perron P; Hudson TJ; Vohl MC; Gaudet D
    Pharmacogenetics; 2002 Jun; 12(4):313-20. PubMed ID: 12042669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The potential insulin sensitizing and glucose lowering effects of a novel indole derivative in vitro and in vivo.
    Li YY; Wu HS; Tang L; Feng CR; Yu JH; Li Y; Yang YS; Yang B; He QJ
    Pharmacol Res; 2007 Oct; 56(4):335-43. PubMed ID: 17889553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.
    Orasanu G; Ziouzenkova O; Devchand PR; Nehra V; Hamdy O; Horton ES; Plutzky J
    J Am Coll Cardiol; 2008 Sep; 52(10):869-81. PubMed ID: 18755353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antidiabetic effect of a novel non-thiazolidinedione PPAR gamma/alpha agonist on ob/ob mice.
    Hu X; Feng Y; Shen Y; Zhao XF; Yu JH; Yang YS; Leng Y
    Acta Pharmacol Sin; 2006 Oct; 27(10):1346-52. PubMed ID: 17007742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.